Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5398MR)

This product GTTS-WQ5398MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5398MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1794MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ2835MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ3135MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ6669MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ13132MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ7242MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ14592MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ4556MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW